Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 5/2015

01.12.2015 | original article

Deterioration of renal function at stent implantation can predict long-term outcome after stent thrombosis

verfasst von: MD Vojko Kanic, PhD Meta Penko, PhD Franjo Husam Naji, PhD Robert Ekart, MD Zlatka Kanic, Prof. Dejan Dinevski, Prof. Radovan Hojs

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 5/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Objectives

The aim of the study was to examine the possible influence of minor deterioration of the renal function after stent implantation not fulfilling the criteria for acute kidney injury on long-term outcomes after stent thrombosis (ST).

Background

Decreased renal function (DRF) is associated with an increased risk for worse outcome after percutaneous coronary intervention. There is no data if the deterioration of renal function after stent implantation influences the prognosis after ST. If so patients with a higher risk for worse outcome after ST could be identified already at the time of stent implantation.

Methods

Data from 4824 consecutive patients treated with percutaneous coronary intervention in our center was recorded from March 2004 to April 2010. We excluded patients with acute kidney injury at stent implantation and 86 of them with ST without acute kidney injury at stent implantation were involved in the study. They were prospectively followed until December 2012 for 50.2 ± 28.1 months. Only patients with definite ST were included in the study. The Academic Research Consortium definition of ST was used. Data on death, myocardial infarction, and repeated percutaneous or operative revascularization after ST were ascertained from the hospital database, by phone or with clinical examinations. The outcomes after definite ST were compared in patients with and without deterioration of renal function after stent implantation (DRFafterSI).

Results

During the observational period patients with DRFafterSI had a higher mortality rate after ST than patients without DRFafterSI (35.1 vs. 10.3 %; p <0.019). The incidence of major adverse cardiac events (major adverse coronary event (MACE)—death, myocardial infarction, repeated revascularization) rate after ST was similar in both groups (66.1 % with DRFafterSI vs. 55.2 % without DRFafterSI). The prevalence of myocardial infarction was also similar in both groups (31.6 vs. 34.5 %) as was the revascularizations rate (43.9 vs. 48.3 %). Death was predicted by DRFafterSI (adjusted hazard ratio (HR) 3.96; 95 % confidence interval (CI) 1.11 to 14.10; p <0.034) and age > 75 years (adjusted HR 2.85: 95 % CI 1.12–7.30; p = 0.029). We could not find any predictor for MACE.

Conclusions

Even more subtle DRFafterSI (not fulfilling the criteria for acute kidney injury) at stent implantation were associated with higher long-term mortality after ST. Especially at risk were patients older than 75 years at stent implantation. DRFafterSI and age more than 75 years pointed out the group of patients with a high risk for death after ST already at the time of stent implantation. The best treatment option for preventing ST in these patients is still to be determined. Until then, we must pay a special attention to proper patients’ preparation and hydration to avoid DRFafterSI.
Literatur
1.
Zurück zum Zitat Windecker S, O’Sullivan CJ. Mitigating the Risk of Early Stent Thrombosis. J Am Coll Cardiol. 2014;63(23):2521–4. CrossRefPubMed Windecker S, O’Sullivan CJ. Mitigating the Risk of Early Stent Thrombosis. J Am Coll Cardiol. 2014;63(23):2521–4. CrossRefPubMed
2.
Zurück zum Zitat Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J. 2005;26(12):1180–7. CrossRefPubMed Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J. 2005;26(12):1180–7. CrossRefPubMed
3.
Zurück zum Zitat Holmes DR, Kereiakes DJ, Garg S, et al. Stent Thrombosis. J Am Coll Cardiol. 2010;56(17):1357–65. CrossRefPubMed Holmes DR, Kereiakes DJ, Garg S, et al. Stent Thrombosis. J Am Coll Cardiol. 2010;56(17):1357–65. CrossRefPubMed
4.
Zurück zum Zitat Akin I, Nienaber CA, Richardt G, et al. Risk factors for clinical events at 1-year follow-up after drug-eluting stent implantation: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol. 2014;103(5):363–72. CrossRefPubMed Akin I, Nienaber CA, Richardt G, et al. Risk factors for clinical events at 1-year follow-up after drug-eluting stent implantation: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol. 2014;103(5):363–72. CrossRefPubMed
5.
Zurück zum Zitat Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. J Am Coll Cardiol Intv. 2012;5(2):131–40. CrossRef Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. J Am Coll Cardiol Intv. 2012;5(2):131–40. CrossRef
6.
Zurück zum Zitat De Luca G, Dirksen MT, Spaulding C, et al. Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111(9):1295–304. CrossRefPubMed De Luca G, Dirksen MT, Spaulding C, et al. Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111(9):1295–304. CrossRefPubMed
7.
Zurück zum Zitat Almalla M, Schröder J, Hennings V, Marx N, Hoffmann R. Long-term outcome after angiographically proven coronary stent thrombosis. Am J Cardiol. 2013;111(9):1289–94. CrossRefPubMed Almalla M, Schröder J, Hennings V, Marx N, Hoffmann R. Long-term outcome after angiographically proven coronary stent thrombosis. Am J Cardiol. 2013;111(9):1289–94. CrossRefPubMed
8.
Zurück zum Zitat Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119(12):1056–61. CrossRefPubMed Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119(12):1056–61. CrossRefPubMed
9.
Zurück zum Zitat Ong ATL, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45(6):947–53. CrossRefPubMed Ong ATL, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45(6):947–53. CrossRefPubMed
10.
Zurück zum Zitat Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents observations from the registry of stent thrombosis for review and reevaluation. Circulation. 2010;122(1):52–61. CrossRefPubMed Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents observations from the registry of stent thrombosis for review and reevaluation. Circulation. 2010;122(1):52–61. CrossRefPubMed
11.
Zurück zum Zitat Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation, of drug-eluting stents. JAMA. 2005;293(17):2126–30. CrossRefPubMed Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation, of drug-eluting stents. JAMA. 2005;293(17):2126–30. CrossRefPubMed
12.
Zurück zum Zitat Marzocchi A, Saia F, Piovaccari G, et al. Long-term safety and efficacy of drug-eluting stents two-year results of the REAL (REgistro AngiopLastiche dell’Emilia Romagna) multicenter registry. Circulation. 2007;115(25):3181–8. CrossRefPubMed Marzocchi A, Saia F, Piovaccari G, et al. Long-term safety and efficacy of drug-eluting stents two-year results of the REAL (REgistro AngiopLastiche dell’Emilia Romagna) multicenter registry. Circulation. 2007;115(25):3181–8. CrossRefPubMed
13.
Zurück zum Zitat Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era analysis of a single center registry. J Am Coll Cardiol. 2002;40(9):1567–72. CrossRefPubMed Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era analysis of a single center registry. J Am Coll Cardiol. 2002;40(9):1567–72. CrossRefPubMed
14.
Zurück zum Zitat Cutlip DE, Baim DS, Ho KKL, et al. Stent thrombosis in the modern era a pooled analysis of multicenter coronary stent clinical trial. Circulation. 2001;103(15):1967–71. CrossRefPubMed Cutlip DE, Baim DS, Ho KKL, et al. Stent thrombosis in the modern era a pooled analysis of multicenter coronary stent clinical trial. Circulation. 2001;103(15):1967–71. CrossRefPubMed
15.
Zurück zum Zitat Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41(8):1364–72. CrossRefPubMed Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41(8):1364–72. CrossRefPubMed
16.
Zurück zum Zitat Bevc S, Ekart R, Hojs R. Cystatin c—a marker of kidney function and predictor of cardiovascular disease and mortality. Acta Medico Biotech. 2014;7(1):9–15. CrossRef Bevc S, Ekart R, Hojs R. Cystatin c—a marker of kidney function and predictor of cardiovascular disease and mortality. Acta Medico Biotech. 2014;7(1):9–15. CrossRef
17.
Zurück zum Zitat Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS). Am Heart J. 2005;149(3):512–9. CrossRefPubMed Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS). Am Heart J. 2005;149(3):512–9. CrossRefPubMed
18.
Zurück zum Zitat Best PJM, Lennon R, Ting H, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39(7):1113–9. CrossRefPubMed Best PJM, Lennon R, Ting H, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39(7):1113–9. CrossRefPubMed
19.
Zurück zum Zitat Barthelemy O, Helft G, Silvain J, et al. One-year clinical outcomes in patients with chronicrenal failure treated by percutaneous coronary intervention with drug-eluting stent. Arch Cardiovasc Dis. 2011;104(12):604–10. CrossRefPubMed Barthelemy O, Helft G, Silvain J, et al. One-year clinical outcomes in patients with chronicrenal failure treated by percutaneous coronary intervention with drug-eluting stent. Arch Cardiovasc Dis. 2011;104(12):604–10. CrossRefPubMed
20.
Zurück zum Zitat Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation. 2000;102(24):2966–72. CrossRefPubMed Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation. 2000;102(24):2966–72. CrossRefPubMed
21.
Zurück zum Zitat Parikh PB, Jeremias A, Naidu SS, et al. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012;80(3):352–7. CrossRefPubMed Parikh PB, Jeremias A, Naidu SS, et al. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012;80(3):352–7. CrossRefPubMed
22.
Zurück zum Zitat Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation. 2002;105(19):2253–8. CrossRefPubMed Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation. 2002;105(19):2253–8. CrossRefPubMed
23.
Zurück zum Zitat Choi DH, Park KW, Yang HM, et al. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol. 2011;149(2):174–81. CrossRefPubMed Choi DH, Park KW, Yang HM, et al. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol. 2011;149(2):174–81. CrossRefPubMed
24.
Zurück zum Zitat Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020–9. CrossRefPubMed Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020–9. CrossRefPubMed
25.
Zurück zum Zitat Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51. CrossRefPubMed Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51. CrossRefPubMed
26.
Zurück zum Zitat Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–141. CrossRef Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–141. CrossRef
27.
Zurück zum Zitat World Health Organization editor. International statistical classification of diseases and related health problems. 10th Revision. Geneva: WHO Press; 2010. World Health Organization editor. International statistical classification of diseases and related health problems. 10th Revision. Geneva: WHO Press; 2010.
28.
Zurück zum Zitat Louvard Y, Medina A, Stankovic G. Definitions and classification of bifurcation lesions and treatment. Eurointervention. 2010;6(suppl J):J31–5. CrossRefPubMed Louvard Y, Medina A, Stankovic G. Definitions and classification of bifurcation lesions and treatment. Eurointervention. 2010;6(suppl J):J31–5. CrossRefPubMed
29.
Zurück zum Zitat Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–93. CrossRefPubMed Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–93. CrossRefPubMed
30.
Zurück zum Zitat Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions. Circulation. 2007;115(6):813–8. CrossRefPubMed Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions. Circulation. 2007;115(6):813–8. CrossRefPubMed
31.
Zurück zum Zitat Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement results from the PREMIER registry. Circulation. 2006;113(24):2803–9. CrossRefPubMed Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement results from the PREMIER registry. Circulation. 2006;113(24):2803–9. CrossRefPubMed
32.
Zurück zum Zitat Wiviot SD, Braunwald E, McCabe KH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial. Lancet. 2008;371(9621):1353–63. CrossRef Wiviot SD, Braunwald E, McCabe KH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial. Lancet. 2008;371(9621):1353–63. CrossRef
33.
Zurück zum Zitat Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98(3):352–6. CrossRefPubMed Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98(3):352–6. CrossRefPubMed
34.
Zurück zum Zitat Gupta S, Cigarroa JE. Bleeding, a call to action. Catheter Cardiovasc Interv. 2014;83(2):190–1. CrossRefPubMed Gupta S, Cigarroa JE. Bleeding, a call to action. Catheter Cardiovasc Interv. 2014;83(2):190–1. CrossRefPubMed
35.
Zurück zum Zitat Attallah N, Yassine L, Fisher K, et al. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol. 2005;64(6):412–8. CrossRefPubMed Attallah N, Yassine L, Fisher K, et al. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol. 2005;64(6):412–8. CrossRefPubMed
36.
Zurück zum Zitat Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374(9696):1149–59. CrossRefPubMed Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374(9696):1149–59. CrossRefPubMed
37.
Zurück zum Zitat Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930–5. CrossRefPubMed Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930–5. CrossRefPubMed
38.
Zurück zum Zitat Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. CrossRefPubMed Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. CrossRefPubMed
39.
Zurück zum Zitat Ndrepepa G, Neumann FJ, Cassese S, et al. Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. Clin Res Cardiol. 2014;103(1):49–56. CrossRefPubMed Ndrepepa G, Neumann FJ, Cassese S, et al. Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. Clin Res Cardiol. 2014;103(1):49–56. CrossRefPubMed
Metadaten
Titel
Deterioration of renal function at stent implantation can predict long-term outcome after stent thrombosis
verfasst von
MD Vojko Kanic
PhD Meta Penko
PhD Franjo Husam Naji
PhD Robert Ekart
MD Zlatka Kanic
Prof. Dejan Dinevski
Prof. Radovan Hojs
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 5/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0844-1